The FDA has published its long-awaited update to guidance to make sure clinical trials more closely reflect the range of patients that might be treated with a new therapy in the real world.
A survey of pharma industry executives has found that a third of them believe mistrust in the healthcare system has become a significant barrier to getting a diverse range of people to sign
Gilead Sciences has said it will soon start a clinical trial in Europe of its twice-yearly HIV injection Sunlenca for pre-exposure prophylaxis (PrEP), a potential successo
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.